Document is current
Any future updates will be listed below
-
Authors
Gründemann, Carsten https://orcid.org/0000-0003-0240-0342
Stenberg, Kjell G.
Gruber, Christian W. https://orcid.org/0000-0001-6060-7048
-
Funding
Funding for this research was provided by:
Austrian Science Fund (P24743, I3243)
Austria Wirtschaftsservice (Prize-P1308423)
Australian Research Council (FT140100730)
DAMUS-DONATA e.V.
Software AG Foundation
- License Information
-
More Information
Article History
Accepted: 24 March 2018
First Online: 5 April 2018
Compliance with Ethical Standards
:
: C.G. and C.W.G. are inventors of the patent “Pharmaceutical composition for treating or preventing disorder e.g. autoimmune disorder, hypersensitivity disorder comprises a cyclotide for use in immunosuppression, optionally carrier, excipient or diluent” (Patent No.: WO2013093045-A2; WO2013093045-A3; AU2012356772-A1; CA2859708-A1; EP2793923-A2; US2014369930-A1; US2016039882-A9; RU2014129918-A; US9453052-B2; US2016367626-A1; AU2012356772-B2; US2017239327-A9; AU2017232191-A1), and serve as members of the scientific advisory board of Cyxone AB (). K.J.S is CEO and shareholder of Cyxone AB.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
